Risk of adverse gastrointestinal events from inhaled corticosteroids

Pharmacotherapy

Volumn 28, Issue 11 PART 1, 2008, Pages 1325-1334

  Hansen, Richard A ^a   Tu, Wanzhu ^b   Wang, Jane ^b   Ambuehl, Roberta ^b   McDonald, Clement J ^b,c   Murray, Michael D ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b REGENSTRIEF INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Gastrointestinal adverse events; Inhaled corticosteroids; Obstructive airways disease; Spacer

Indexed keywords

ALENDRONIC ACID; BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; ETIDRONIC ACID; FLUNISOLIDE; FLUTICASONE; IRON; MOMETASONE FUROATE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; RISEDRONIC ACID; SALBUTAMOL; THEOPHYLLINE; TRIAMCINOLONE;

ADULT; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG USE; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEALTH SERVICE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH ULCER; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55549090341     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.11.1325     Document Type: Article

References (35)

1. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107:937-44.
2. Sin DD, Tu JV. Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics. Eur Respir J 2001;17:380-5.
3. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 2004;292:367-76.
4. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992;268:3462-4.
5. Navarro RP, Parasuraman B. Cost effectiveness of asthma controller therapies: influence of disease severity and other variables. Manag Care Interface 2005;18:31-40.
6. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
7. van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54:7-14.
8. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003;168:1488-94.
9. Johansson SA, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis Suppl 1982;122:74-82.
10. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics - 2002. J Allergy Clin Immunol 2002;110(5 suppl):S141-219.
11. Macdessi JS, Randell TL, Donaghue KC, Ambler GR, van Asperen PP, Mellis CM. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Med J Aust 2003;178:214-16.
12. Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 2002;34:85-6.
13. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
14. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. AmJ Respir Crit Care Med 2004;169:855-9.
15. van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581-8.
16. Sharek PJ, Bergman DA, Ducharme F. Beclomethasone for asthma in children: effects on linear growth. Cochrane Database Syst Rev 2000;(3):CD001282.
17. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
18. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998;280:539-43.
19. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 2001;12:229-34.
20. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. Br J Ophthalmol 2003;87:1247-51.
21. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277:722-7.
22. Mitchell P, Cumming RG, Mackey DA. Inhaled corticosteroids, family history, and risk of glaucoma. Ophthalmology 1999;106:2301-6.
23. Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51.
24. Mak VH, Melchor R, Spiro SG. Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J 1992;5:1068-74.
25. Tashkin DP, Murray HE, Skeans M, Murray RP. Skin manifestations of inhaled corticosteroids in COPD patients: results from lung health study II. Chest 2004;126:1123-33.
26. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-4.
27. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991;114:735-40.
28. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153:1089-93.
29. Barnes NC. Safety of high-dose inhaled corticosteroids. Respir Med 1993;87(supplA):27-31.
30. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006;100:1307-17.
31. Murray MD, Loos B, Tu W, Eckert GJ, Zhou XH, Tierney WM. Work patterns of ambulatory care pharmacists with access to electronic guideline-based treatment suggestions. Am J Health Syst Pharm 1999;56:225-32.
32. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 11 (suppl):S1-40.
33. Trescoli C, Ward MJ. Systemic activity of inhaled and swallowed beclomethasone dipropionate and the effect of different inhaler devices. Postgrad Med J 1998;74:675-7.
34. Newman SP, Newhouse MT. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects. J Aerosol Med 1996;9:55-70.
35. Ahrens R, Lux C, Bahl T, Han SH. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 1995;96:288-94.